Privo Technologies
Mass. · Biopharma, Biotechnology, Health Care
Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eli
Key facts
- Headquarters
- Mass.
- Employees
- 13
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- privotechnologies.com
- Company page
Recent activity at Privo Technologies
- : Privo Technologies, LLC secured a $1,170,285 NIH SBIR/STTR award: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
- : Privo Technologies, Inc. Appoints Dr. Albert Collinson as Independent Non-Executive Director
Privo Technologies funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Grant | $1.2M |
Leadership
- Stefanie Cantin, Senior Director of Operations and Quality Assurance
- Shruti Chandrashekar, Research Scientist
- Albert Collinson, Independent Non Executive Director
Verified email and direct lines for Privo Technologies’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Privo Technologies in the news
- /C O R R E C T I O N -- Privo Technologies/ - Yahoo Finance (Oct 07, 2026)
- Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors - BioSpace (Feb 25, 2022)
- PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial - PR Newswire (Nov 17, 2025)
Companies similar to Privo Technologies
- TNF Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- LTR Pharma Limited · Biopharma, Biotechnology, Health Care, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- Sorriso Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Ensho Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
About Privo Technologies: questions and answers
What does Privo Technologies do?
Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eli
Where is Privo Technologies headquartered?
Privo Technologies is headquartered in Mass..
How many employees does Privo Technologies have?
Privo Technologies has about 13 employees.
Has Privo Technologies raised funding?
Yes. Fundz has recorded 1 funding event for Privo Technologies. The most recent, Grant of $1.2M, was in Jun 2026.
What is the latest news on Privo Technologies?
On Jun 18, 2026, Privo Technologies, LLC secured a $1,170,285 NIH SBIR/STTR award: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy